Brokerages Anticipate Heron Therapeutics, Inc. (NASDAQ:HRTX) Will Post Quarterly Sales of $4.53 Million

Equities analysts expect that Heron Therapeutics, Inc. (NASDAQ:HRTX) will announce sales of $4.53 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Heron Therapeutics’ earnings, with the highest sales estimate coming in at $4.70 million and the lowest estimate coming in at $4.36 million. The firm is scheduled to announce its next quarterly earnings report on Monday, August 14th.

On average, analysts expect that Heron Therapeutics will report full year sales of $4.53 million for the current financial year, with estimates ranging from $21.02 million to $22.90 million. For the next fiscal year, analysts expect that the firm will report sales of $83.90 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.94) by $0.06. The business had revenue of $3.63 million for the quarter, compared to analysts’ expectations of $1.96 million.

HRTX has been the subject of several analyst reports. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a report on Friday, May 12th. Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 9th. Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, August 3rd. Aegis restated a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a report on Tuesday, July 18th. Finally, Jefferies Group LLC restated a “buy” rating and set a $26.00 price target on shares of Heron Therapeutics in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $31.00.

Several large investors have recently added to or reduced their stakes in HRTX. Airain ltd acquired a new stake in Heron Therapeutics during the second quarter valued at approximately $442,000. Royce & Associates LP acquired a new stake in Heron Therapeutics during the second quarter valued at approximately $796,000. Legal & General Group Plc boosted its stake in Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 2,383 shares during the period. Bank of New York Mellon Corp boosted its stake in Heron Therapeutics by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock valued at $2,837,000 after buying an additional 14,086 shares during the period. Finally, State of Wisconsin Investment Board acquired a new stake in Heron Therapeutics during the second quarter valued at approximately $457,000.

Heron Therapeutics (NASDAQ HRTX) opened at 15.85 on Wednesday. The firm’s 50-day moving average is $15.24 and its 200-day moving average is $14.47. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $24.00.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Heron Therapeutics, Inc. (NASDAQ:HRTX) Will Post Quarterly Sales of $4.53 Million” was first reported by BNB Daily and is the sole property of of BNB Daily. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/brokerages-anticipate-heron-therapeutics-inc-nasdaqhrtx-will-post-quarterly-sales-of-4-53-million-updated.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply